#ScienceLink #Madrid2026 #ESMO26 #OptiTROPBreast01 #SacituzumabTirumotecán
在 OptiTROP-Breast01（III期；n=263）中，对于既往接受≥2线系统治疗（转移性疾病中≥1线）的局部复发或转移性三阴性乳腺癌，sacituzumab tirumotecán 相较于研究者选择的 QT 维持了 SG 获益。
⏰ 中位随访时间：29.4个月。
📊 中位 SG：14.7 vs 9.9个月。
HR 0.60（95% CI：0.45–0.80；名义 p=0.0004）。
📈 30个月 SG：26.8% vs 13.2%。
⚠️ 延长随访期间未发现新的安全性信号。
🔗 阅读/收听完整新闻：https://buff.ly/0K4UAO3
10 浏览 · 0 赞 · 0 转发 · 0 回复
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgTroFuse-021/ENGOT-ov85/GOG-3102: Phase 3 study of maintenance sacituzumab tirumotecan (Sac-TMT) with or without bevacizumab versus standard of care in patients with advanced ovarian cancer
https://esmocongress.esmo.orgNeoadjuvant sacituzumab govitecan plus pembrolizumab in resectable non-small cell lung cancer: Phase II CITADEL study
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.org来源：ScienceLink · x.com